查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134969

全球脊髓性肌肉萎縮症 (SMA) 治療管線分析，2026 年（第二季洞察與臨床試驗）

Global Spinal Muscular Atrophy (SMA) Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

脊髓性肌肉萎縮症 (SMA) 的治療研發管線不斷從第一代疾病修正治療發展到以改善運動功能、肌肉力量、長期療效和生活品質為重點的創新方法，為製藥和生物技術公司創造了一個高度動態的環境。

脊髓性肌肉萎縮症 (SMA) 是一種罕見的遺傳性神經肌肉疾病，主要由 SMN1 基因突變或缺失引起，導致運動神經元進行性退化和肌肉無力。儘管已通過核准的治療方法透過延長存活期和延緩疾病進展顯著改善了疾病管理，但仍存在大量未被滿足的需求，尤其是在那些遺留運動功能障礙的患者中。因此，製藥公司正積極研發能夠透過新的作用機制補充現有 SMN 標靶療法的療法。藥物研發管線的分析能夠提供關於在研藥物、臨床開發進展、作用機制、治療方法、監管里程碑、研發人員活動以及未來商業化機會等方面的寶貴資訊。

市場促進因素

拓展SMA藥物研發領域的創新

  • 市場成長的主要驅動力之一是針對SMN依賴性和SMN非依賴性疾病路徑的創新療法計畫的快速發展。雖然目前的療法能夠有效提高SMN蛋白的生成，但研發人員正日益關注改善肌肉功能、神經肌肉功能和長期功能預後的治療方法。
  • 隨著臨床實驗藥物種類日益增多，聯合治療和個人化治療策略的機會也隨之擴大。

增加基因療法和RNA療法的投資

  • 基因替代療法和RNA藥物的成功推動了對先進基因治療平台的持續投資。各公司正積極開發下一代基因療法、RNA療法、生物製藥和精準醫療方法，以期提高療效、擴大患者群體並增強長期安全性。

擴大新生兒篩檢計劃

  • 多個國家引入新生兒篩檢項目，使得在發生不可逆的運動神經元損傷之前，能夠儘早診斷並啟動治療。早期介入不僅能增強疾病修正治療的潛在療效，也能擴大未來在研藥物的適用患者族群。

支持性的法規環境

  • 監管機構持續透過孤兒藥認定、加速核准流程、優先審查項目和罕見疾病獎勵來促進創新。這些監管機制降低了研發風險，並鼓勵對多種治療平台進行持續投資。

市場限制因素

患者數量少

  • SMA 仍然是一種罕見疾病，全球患者數量有限，這使得招募臨床試驗參與者更加困難，降低了個別療法的商業性潛力。

高昂的研發成本

  • 先進的基因療法、RNA療法和生物製藥需要在研究、生產、監管合規和長期安全評估方面進行大量投資，這增加了整體開發成本。

複雜的臨床開發

  • 要證明運動功能、活動能力和生活品質 (QOL) 有實質改善，通常需要進行具有特定終點和延長追蹤期的長期臨床試驗。

深入了解製藥研發管線和技術

  • 全球脊髓性肌肉萎縮症 (SMA) 治療藥物研發管線可依研發階段、作用機制、治療方法、研發者類型和地區分類。
  • 依研發階段分類，產品線包括臨床前計畫、I期、II期、III期臨床試驗、正在接受監管審查的藥物。早期和中期研發階段的活躍活動體現了公司對滿足未滿足醫療需求的新型療法的持續投入。
  • 從作用機制來看，此研發管線涵蓋SMN再生療法、SMN2剪接調節劑、基因替代療法、神經保護劑、肌肉特異性療法、再生療法、肌肉生長抑制素抑制劑等新型作用機制。雖然針對SMN的療法仍然是最大的類別，但人們對能夠改善基因矯正之外的功能性結果的肌肉特異性療法和輔助療法的興趣日益濃厚。
  • 從治療方法來看，研發管線包括基因療法、RNA療法、小分子化合物、生技藥品、細胞療法和新興基因醫學平台。
  • 按開發商類型分類，市場包括製藥公司、生技公司、學術研究機構、政府機構和合作開發夥伴關係。
  • 人工智慧、基因組醫學、生物標記發現、數位臨床試驗技術和真實世界數據 (REW) 平台的進步正在改善候選化合物的選擇，簡化臨床試驗，促進監管決策，並制定未來的商業化策略。

管道開發趨勢

  • SMA 治療藥物的研發方向正逐漸從直接與已通過核准的SMN 標靶療法競爭，轉向旨在補充現有標準療法的療法。

目前主要的發展趨勢如下：

  • 開發聯合治療以改善現有療法的效果。
  • 擴大直接作用於肌肉的治療方法，以解決殘餘肌肉無力問題。
  • 增加對肌肉生長抑制素抑制劑和再生醫學的投資。
  • 新一代基因療法，具有更高的永續性和更廣泛的適應症。
  • 一種利用基因生物標記實現個人化治療方案的精準醫療方法。
  • 策略聯盟、授權協議和研究夥伴關係持續加速產品線擴張和治療創新。

區域趨勢

  • 北美憑藉其強大的生物技術基礎設施、廣泛的新生兒篩檢、先進的基因檢測、大量的研究資金和支持性的孤兒藥法規，仍然是 SMA 治療研發的領先地區。
  • 在罕見疾病合作研究、有利的監管政策以及廣泛參與跨國臨床開發計畫的支持下，歐洲已成為另一個重要的創新中心。
  • 預計亞太地區將在預測期內實現最快成長，這主要得益於生物技術能力的提升、醫療保健投資的增加、基因診斷基礎設施的改善，以及日本、中國、韓國、印度和澳洲等國在全球臨床研究中參與度的提高。
  • 在拉丁美洲、中東和非洲，隨著醫療基礎設施的改善、診斷系統的擴展以及更多參與國際藥物開發計劃，對罕見疾病的研究正在逐步加強。

競爭格局

  • SMA治療藥物研發管線競爭非常激烈，全球製藥公司、生技公司、學術研究機構以及新興罕見疾病領域的創新者都在進入該市場。
  • 開發商正大力投資基因療法、RNA療法、肌肉標靶生物製藥、再生醫學、神經保護劑和精準醫療平台。策略聯盟、授權協議、併購和共同開發夥伴關係進一步豐富了產品線，並加速了產品開發進程。
  • 競爭日益集中在以下幾個方面：運動功能顯著改善、患者適用範圍更廣、治療效果持續時間更長、安全性更高，以及聯合治療策略來解決殘餘疾病負擔。

未來展望

  • 脊髓性肌肉萎縮症（SMA）治療的未來發展預計將受到基因編輯、RNA療法、再生醫學、人工智慧、生物標記發現和精準醫療等領域進步的推動。未來的治療目標不僅在於穩定病情，還包括恢復神經肌肉功能、提升長期獨立生活能力和改善生活品質。
  • 隨著對 SMA 的科學認知不斷發展，製藥公司有望開發出越來越個人化的治療策略，將基因矯正、肌肉標靶療法和新的生物學機制結合起來。

結論

  • 全球脊髓性肌肉萎縮症 (SMA) 藥物研發管線分析市場預計將持續成長至 2035 年，主要促進因素包括對罕見疾病治療投資的增加、基因療法的持續創新、新生兒篩檢的普及以及監管支持的加強。儘管患者群體有限、研發成本高昂以及臨床試驗複雜等挑戰依然存在，但基因療法、RNA 療法、再生醫學和精準醫學的進步有望顯著改變未來的治療方案。不斷擴展的研發管線為製藥公司、生技公司、投資者和醫療保健機構提供了巨大的機遇，協助他們滿足 SMA 患者未被滿足的醫療需求。

本報告的主要益處

  • 深入分析：對全球 SMA 治療產品線、臨床實驗中的療法以及新興治療趨勢進行全面評估。
  • 競爭格局：對管道資產、開發商、營運機制和策略定位進行詳細評估。
  • 市場促進因素與未來趨勢：藥物研發創新趨勢、監管趨勢與未來機會分析。
  • 實用建議：為許可、投資、合作夥伴關係評估、投資組合管理和商業化規劃提供支援的策略性見解。
  • 本書適合廣泛的讀者群體：本書為製藥公司、生技公司、投資者、研究人員、合約研究組織、醫療保健提供者和政策制定者提供了有價值的資訊。

我們的報告的使用情況

  • 管線基準分析、藥物開發策略、競爭情報分析、許可評估、合作夥伴識別、投資分析、監管合規規劃、產品組合最佳化以及未來商業化機會的識別。

調查範圍

  • 歷史資料涵蓋 2021 年至 2025 年，基準年為 2025 年，預測期間為 2026 年至 2035 年。
  • 從研發階段、作用機轉、治療方法和地區等方面對全球SMA藥物研發管線進行全面分析。
  • 對管線資產、臨床開發進展、監管里程碑以及技術和商業性成功潛力進行評估。
  • 開發公司趨勢、授權活動、策略聯盟、併購和投資趨勢的分析。
  • 評估新興治療技術、創新趨勢、競爭地位和未來研發管線機會。
  • 策略性展望涵蓋商業化前景、未滿足的需求以及 2035 年藥物開發的未來趨勢。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：脊髓性肌肉萎縮症（SMA）治療研發管線的發展趨勢

  • 促進因素
  • 抑制因子
  • 潛在機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Biogen
    • Roche
    • Novartis
    • Scholar Rock
    • Astellas Pharma
    • 羅氏
  • 管道分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • 嬰兒型/1型脊髓性肌肉萎縮症
    • 2 型 SMA
    • 3型/晚髮型脊髓性肌肉萎縮症
    • 既往接受過治療的SMA
  • 研發管線分析：依臨床試驗狀態分類
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前已暫停招募參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 關於患者年齡的合格標準
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 贊助商和合作研究者分析
  • 近期和未來管道趨勢
    • 近期啟動的臨床試驗
    • 目前正在招募受試者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗即將完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Biogen
  • Roche
  • Novartis
  • Scholar Rock
  • Astellas Pharma

第7章 圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008930

The SMA pipeline continues to evolve from first-generation disease-modifying therapies toward innovative approaches focused on improving motor function, muscle strength, long-term durability, and quality of life, creating a highly dynamic environment for pharmaceutical and biotechnology companies.

Spinal Muscular Atrophy (SMA) is a rare inherited neuromuscular disorder primarily caused by mutations or deletions in the SMN1 gene, resulting in progressive degeneration of motor neurons and muscle weakness. Although approved therapies have transformed disease management by increasing survival and slowing disease progression, significant unmet needs remain, particularly among patients with residual motor impairment. Consequently, drug developers are actively pursuing therapies that complement existing SMN-targeted treatments through novel mechanisms of action. Drug pipeline analysis provides valuable insights into investigational assets, clinical development progress, mechanisms of action, therapeutic modalities, regulatory milestones, developer activities, and future commercialization opportunities.

Market Drivers

Growing Innovation in SMA Drug Development

  • One of the primary drivers of market growth is the rapid expansion of innovative therapeutic programs targeting both SMN-dependent and SMN-independent disease pathways. While current therapies successfully increase SMN protein production, developers are increasingly focusing on therapies that improve muscle function, neuromuscular performance, and long-term functional outcomes.
  • The growing diversity of investigational drugs has expanded opportunities for combination therapies and personalized treatment strategies.

Increasing Investment in Gene and RNA Therapeutics

  • The success of gene replacement therapy and RNA-based medicines has encouraged continued investment in advanced genetic medicine platforms. Companies are actively developing next-generation gene therapies, RNA therapeutics, biologics, and precision medicine approaches that offer improved efficacy, broader patient eligibility, and enhanced long-term safety.

Expansion of Newborn Screening Programs

  • The implementation of newborn screening programs across multiple countries has enabled earlier diagnosis and treatment initiation before irreversible motor neuron loss occurs. Earlier intervention increases the potential benefits of disease-modifying therapies while expanding the addressable patient population for future pipeline assets.

Supportive Regulatory Environment

  • Regulatory agencies continue to promote innovation through orphan drug designation, accelerated approval pathways, priority review programs, and rare disease incentives. These regulatory mechanisms reduce development risk and encourage continued investment across multiple therapeutic platforms.

Market Restraints

Small Patient Population

  • SMA remains a rare disease with a limited global patient population, making clinical trial recruitment more challenging and reducing the commercial potential for individual therapies.

High Research and Development Costs

  • Advanced gene therapies, RNA therapeutics, and biologics require substantial investment in research, manufacturing, regulatory compliance, and long-term safety evaluation, increasing overall development costs.

Complex Clinical Development

  • Demonstrating meaningful improvements in motor function, mobility, and quality of life often requires lengthy clinical studies with specialized endpoints and extended follow-up periods.

Drug Pipeline and Technology Insights

  • The global SMA drug pipeline can be segmented by development phase, mechanism of action, therapeutic modality, developer type, and geography.
  • By development phase, the pipeline includes preclinical programs, Phase I, Phase II, Phase III, and regulatory review-stage assets. Strong activity across early- and mid-stage development reflects sustained investment in novel therapies addressing unmet clinical needs.
  • By mechanism of action, the pipeline includes SMN restoration therapies, SMN2 splicing modifiers, gene replacement therapies, neuroprotective agents, muscle-targeted therapies, regenerative therapies, myostatin inhibitors, and other emerging mechanisms. While SMN-targeted therapies remain the largest category, increasing attention is being directed toward muscle-directed and complementary therapies that improve functional outcomes beyond genetic correction.
  • By therapeutic modality, the pipeline includes gene therapies, RNA therapeutics, small molecules, biologics, cell-based therapies, and emerging genetic medicine platforms.
  • By developer type, the market includes pharmaceutical companies, biotechnology firms, academic research institutions, government organizations, and collaborative development partnerships.
  • Advances in artificial intelligence, genomic medicine, biomarker discovery, digital clinical trial technologies, and real-world evidence platforms are improving candidate selection, clinical trial efficiency, regulatory decision-making, and future commercialization strategies.

Pipeline Development Trends

  • The SMA drug pipeline is increasingly shifting toward therapies designed to complement existing standards of care rather than directly compete with approved SMN-targeted treatments.

Major pipeline trends include:

  • Development of combination therapies that enhance existing treatment outcomes.
  • Expansion of muscle-directed therapies targeting residual weakness.
  • Increasing investment in myostatin inhibitors and regenerative medicine.
  • Next-generation gene therapies with improved durability and broader treatment eligibility.
  • Precision medicine approaches utilizing genetic biomarkers for individualized therapy selection.
  • Strategic collaborations, licensing agreements, and research partnerships continue to accelerate pipeline expansion and therapeutic innovation.

Regional Insights

  • North America remains the leading region for SMA drug development due to strong biotechnology infrastructure, widespread newborn screening, advanced genetic testing, significant research funding, and supportive orphan drug regulations.
  • Europe represents another major innovation hub supported by collaborative rare disease research, favorable regulatory policies, and extensive participation in multinational clinical development programs.
  • Asia-Pacific is expected to register the fastest growth during the forecast period owing to expanding biotechnology capabilities, increasing healthcare investment, improving genetic diagnostic infrastructure, and growing participation in global clinical research across Japan, China, South Korea, India, and Australia.
  • Latin America and the Middle East & Africa are gradually strengthening rare disease research through improving healthcare infrastructure, expanding diagnosis, and increasing participation in international drug development programs.

Competitive Landscape

  • The SMA drug pipeline is highly competitive and includes global pharmaceutical companies, biotechnology firms, academic research institutions, and emerging rare disease innovators.
  • Developers are investing heavily in gene therapies, RNA therapeutics, muscle-directed biologics, regenerative medicine, neuroprotective agents, and precision medicine platforms. Strategic collaborations, licensing agreements, mergers and acquisitions, and co-development partnerships continue to strengthen pipeline diversification and accelerate product development.
  • Competition is increasingly focused on achieving superior motor outcomes, broader patient eligibility, longer treatment durability, improved safety, and combination therapy strategies that address residual disease burden.

Future Outlook

  • The future of the SMA drug pipeline is expected to be driven by continued advances in gene editing, RNA therapeutics, regenerative medicine, artificial intelligence, biomarker discovery, and precision medicine. Future therapies are expected to move beyond disease stabilization toward restoring neuromuscular function, improving long-term independence, and enhancing quality of life.
  • As scientific understanding of SMA continues to evolve, pharmaceutical companies are expected to develop increasingly personalized treatment strategies that combine genetic correction with muscle-targeted therapies and novel biological mechanisms.

Conclusion

  • The global Spinal Muscular Atrophy Drug Pipeline Analysis market is positioned for sustained growth through 2035, supported by expanding investment in rare disease therapeutics, continuous innovation in genetic medicine, increasing newborn screening, and growing regulatory support. While challenges including limited patient populations, high development costs, and complex clinical trials remain, advances in gene therapy, RNA therapeutics, regenerative medicine, and precision medicine are expected to transform the future treatment landscape. The expanding pipeline offers significant opportunities for pharmaceutical companies, biotechnology firms, investors, and healthcare providers seeking to address the remaining unmet needs of patients living with SMA.

Key Benefits of this Report

  • Insightful Analysis: Comprehensive evaluation of the global SMA drug pipeline, investigational therapies, and emerging treatment trends.
  • Competitive Landscape: Detailed assessment of pipeline assets, developers, mechanisms of action, and strategic positioning.
  • Market Drivers and Future Trends: Analysis of innovation trends, regulatory developments, and future drug development opportunities.
  • Actionable Recommendations: Strategic insights supporting licensing, investment, partnership evaluation, portfolio management, and commercialization planning.
  • Caters to a Wide Audience: Valuable for pharmaceutical companies, biotechnology firms, investors, researchers, CROs, healthcare providers, and policymakers.

What Businesses Use Our Reports For

  • Pipeline benchmarking, drug development strategy, competitive intelligence, licensing evaluation, partnership identification, investment analysis, regulatory planning, portfolio optimization, and identification of future commercialization opportunities.

Report Coverage

  • Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global SMA drug pipeline by development phase, mechanism of action, therapeutic modality, and geography
  • Evaluation of pipeline assets, clinical development progress, regulatory milestones, and probability of technical and commercial success
  • Analysis of developer landscape, licensing activities, strategic collaborations, mergers and acquisitions, and investment trends
  • Assessment of emerging therapeutic technologies, innovation trends, competitive positioning, and future pipeline opportunities
  • Strategic outlook covering commercialization prospects, unmet clinical needs, and future drug development trends through 2035

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. SPINAL MUSCULAR ATROPHY (SMA) PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Biogen
    • 5.1.2. Roche
    • 5.1.3. Novartis
    • 5.1.4. Scholar Rock
    • 5.1.5. Astellas Pharma
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. Infantile / Type 1 SMA
    • 5.4.2. Type 2 SMA
    • 5.4.3. Type 3 / Later-Onset SMA
    • 5.4.4. Previously Treated SMA
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Biogen
  • 6.2. Roche
  • 6.3. Novartis
  • 6.4. Scholar Rock
  • 6.5. Astellas Pharma

7. LIST OF TABLES

8. LIST OF FIGURES